Capricor Therapeutics Under Fire: Securities Fraud Lawsuit Filed After Massive Stock Crash

Investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) are now facing the aftermath of a devastating stock decline. In a recent move to protect shareholder interests, the prominent law firm Bleichmar Fonti & Auld LLP has announced the filing of a class action lawsuit alleging securities fraud against the company and its top executives.

The lawsuit centers on allegations that the biotechnology company failed to be transparent about critical regulatory hurdles, leading to significant financial losses for those who trusted the company’s public disclosures.

What Led to the Securities Fraud Allegations?

Capricor Therapeutics has been focusing its efforts on developing Deramiocel, an investigational cell therapy designed to treat Duchenne muscular dystrophy (DMD). However, the path to FDA approval became a point of contention.

According to the legal complaint, the controversy began after Capricor submitted a Biologics License Application (BLA) to the FDA. In July 2025, the FDA issued a Complete Response Letter, stating that the application lacked substantial evidence of effectiveness and required additional clinical data.

The core of the fraud claim: It is alleged that Capricor failed to disclose that it had altered the pre-specified statistical analysis plan for Deramiocel’s clinical data—changes that the FDA had not agreed to prior to the resubmission of the BLA.

The Financial Fallout: A Double Blow to Shareholders

The market’s reaction was swift and brutal once the lack of transparency came to light. The stock experienced two major crashes:

n
• The First Drop: On July 27, 2026, following FDA briefing documents that raised concerns about “post-hoc” changes to the statistical methodology, $CAPR shares plummeted by 64.5%, dropping from $19.70 to $7.00 in a single trading day.
• The Second Drop: On July 30, 2026, after an advisory committee vote concluded that evidence did not support Deramiocel’s efficacy for DMD-associated cardiomyopathy, the stock fell another 36%, ending at $4.19.

For many investors, this sequence of events represents a classic case of securities fraud, where critical information was withheld to maintain an inflated stock price.

Important Deadlines and Legal Options for Investors

If you invested in Capricor Therapeutics securities and suffered losses, you may be entitled to compensation. The class action is currently pending in the U.S. District Court for the Southern District of California (Nkamga v. Capricor Therapeutics, Inc. et al.).

Key Date to Remember: Investors have until September 28, 2026, to request the Court to be appointed as the lead plaintiff in this case.

How to Proceed?

Shareholders are encouraged to seek legal counsel to explore their options. Many firms, including Bleichmar Fonti & Auld LLP, operate on a contingency fee basis, meaning there is no upfront cost to the investor; the firm only receives payment if a recovery is successful.

Understanding Securities Fraud and Investor Protection

Securities fraud occurs when companies provide misleading information or omit material facts to manipulate stock prices. Under the U.S. Securities and Exchange Commission (SEC) guidelines and the Securities Exchange Act of 1934, transparency is mandatory for publicly traded companies on the NASDAQ and other exchanges.

Protecting your investments requires vigilance and, when necessary, legal action to hold corporate executives accountable for their disclosures.

Disclaimer: This article is for informational purposes and does not constitute legal or financial advice. Please consult with a licensed professional regarding your specific investment situation.